Dublin, July 13, 2018 (GLOBE NEWSWIRE) -- The "Pharmaceuticals for Women's Health: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering.
While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders.
Report includes:
- Detailed overview of the global markets for pharmaceuticals for women's health
- Country specific data and analysis for United States, Mexico, Germany, U.K., France, China, India, Japan, Middle East and Africa
- A look at the regulatory environment which has been a driving force in the drug development industry
- Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
- A relevant patent analysis within the sector
- Comprehensive company profiles of major Players in the Market including AbbVie Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson Inc., Novo Nordisk and Pfizer Inc.
Key Topics Covered
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Technologies and Global Markets Overview
- Disease Overview and Definitions
- Market Driving Factors and Opportunities
- Aging Female Population
- Government Involvement and Increased Funding
- Increasing Awareness Regarding Women's Disorders and Treatments
- Market Restraints
- Poor Diagnosis
- Availability of Alternate Treatment Options and Lifestyle Changes
- Unavailability of Novel Treatments
- High Cost of Treatment
Chapter 4 Pipeline Assessment and Analysis
- List of Drugs in Pipeline
- Overview of Osteoporosis Drug Development Pipeline
- Late-stage Pipeline Drugs
- Elagolix (AbbVie Inc.)
- Vilaprisan (Bayer AG)
- Evenity (Amgen Inc.)
- Relugolix (Myovant Sciences)
- Proellex (Repros Therapeutics)
- Esmya (Allergan Inc.)
- TX-004HR (TherapeuticsMD, Inc.)
- TX-001HR (TherapeuticsMD, Inc.)
Chapter 5 Regulatory Structure
- Overview of Regulations
- United States
- Canada
- Europe
- Japan
- Overview of Pricing and Reimbursement
- United States
- Canada
- Europe
- Japan
Chapter 6 Market Breakdown by Women's Health Disorders
- Introduction
- Menopause-Related Diseases
- Overview
- Symptoms
- Risk Factors
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Postmenopausal Osteoporosis
- Overview
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Endometriosis
- Overview
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Polycystic Ovary Syndrome (PCOS)
- Overview
- Reducing the Risk of PCOS
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Pregnancy Disorders and Management
- Overview
- Market Size and Forecasts
- Others
- Overview
- Market Size and Forecasts
Chapter 7 Market Breakdown by Region
- Introduction
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- South America
- Middle East and Africa
Chapter 8 Competitive Landscape and Key Developments
- Market Players and Strategy
- Patent Analysis
- List of Key Patents
- Key Developments
- Mergers and Acquisitions
- Development of Innovative Products/Novel Product Launch
- Agreements, Collaborations & Partnerships
- Key Products
Chapter 9 Company Profiles
- ABBVIE INC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- ALLERGAN PLC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- AMGEN INC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- BAYER AG
- Company Overview
- Product Information
- Development and Strategies
- Financials
- DAIICHI SANKYO COMPANY. LTD.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- ELI LILLY AND COMPANY
- Company Overview
- Product Information
- Development and Strategies
- Financials
- JOHNSON & JOHNSON INC.
- Company Overview
- Product Information
- Financials
- MERCK & CO. INC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- MERCK KGAA
- Company Overview
- Product Information
- NOVO NORDISK
- Company Overview
- Product Information
- Financials
- PFIZER INC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
Chapter 10 Appendix
- Abbreviations Used in the Report
For more information about this report visit https://www.researchandmarkets.com/research/fp3k82/global?w=12